IL290798B2 - Tyrosine kinase inhibitor drug candidates for cancer treatment - Google Patents

Tyrosine kinase inhibitor drug candidates for cancer treatment

Info

Publication number
IL290798B2
IL290798B2 IL290798A IL29079822A IL290798B2 IL 290798 B2 IL290798 B2 IL 290798B2 IL 290798 A IL290798 A IL 290798A IL 29079822 A IL29079822 A IL 29079822A IL 290798 B2 IL290798 B2 IL 290798B2
Authority
IL
Israel
Prior art keywords
tyrosine kinase
kinase inhibitor
cancer treatment
drug candidates
inhibitor drug
Prior art date
Application number
IL290798A
Other languages
Hebrew (he)
Other versions
IL290798A (en
IL290798B1 (en
Original Assignee
Risen Suzhou Pharma Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201910817505.XA external-priority patent/CN112442009B/en
Priority claimed from CN201910818779.0A external-priority patent/CN112442011B/en
Priority claimed from CN201910818675.XA external-priority patent/CN112442010B/en
Application filed by Risen Suzhou Pharma Tech Co Ltd filed Critical Risen Suzhou Pharma Tech Co Ltd
Publication of IL290798A publication Critical patent/IL290798A/en
Publication of IL290798B1 publication Critical patent/IL290798B1/en
Publication of IL290798B2 publication Critical patent/IL290798B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL290798A 2019-08-30 2020-08-28 Tyrosine kinase inhibitor drug candidates for cancer treatment IL290798B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201910817505.XA CN112442009B (en) 2019-08-30 2019-08-30 Deuterated compounds and their use for treating cancer
CN201910818779.0A CN112442011B (en) 2019-08-30 2019-08-30 A prodrug compound and its application in treating cancer
CN201910818675.XA CN112442010B (en) 2019-08-30 2019-08-30 A class of prodrug compounds and their application in treating cancer
US202062994364P 2020-03-25 2020-03-25
PCT/CA2020/051177 WO2021035360A1 (en) 2019-08-30 2020-08-28 Prodrugs of the tyrosine kinase inhibitor for treating cancer

Publications (3)

Publication Number Publication Date
IL290798A IL290798A (en) 2022-04-01
IL290798B1 IL290798B1 (en) 2026-02-01
IL290798B2 true IL290798B2 (en) 2026-06-01

Family

ID=74684795

Family Applications (1)

Application Number Title Priority Date Filing Date
IL290798A IL290798B2 (en) 2019-08-30 2020-08-28 Tyrosine kinase inhibitor drug candidates for cancer treatment

Country Status (5)

Country Link
EP (1) EP4021912A4 (en)
AU (1) AU2020338490B2 (en)
CA (1) CA3147801A1 (en)
IL (1) IL290798B2 (en)
WO (1) WO2021035360A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3232086A1 (en) * 2021-10-15 2023-04-20 Peter Jarrett Prodrugs of axitinib
US20260049071A1 (en) * 2022-08-08 2026-02-19 Beyang Therapeutics Co., Ltd. Protein tyrosine kinase inhibitor and medical use thereof
CN120329323B (en) * 2025-04-16 2026-01-13 黄冈鲁班药业股份有限公司 A method for preparing cefepime side chains and their applications

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001002369A2 (en) * 1999-07-02 2001-01-11 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
CN106336397A (en) * 2015-07-07 2017-01-18 郭明山 Novel compound for treating ophthalmic diseases
CN106478596A (en) * 2015-08-25 2017-03-08 李建成 A kind of noval chemical compound as treatment ophthalmic diseasess

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106317017A (en) 2015-07-10 2017-01-11 李建成 Novel compound used for treating ophthalmic diseases
CN110372598A (en) * 2018-04-13 2019-10-25 成都海创药业有限公司 A kind of new method synthesizing deuterated amide and deuterated sulfonamide

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001002369A2 (en) * 1999-07-02 2001-01-11 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
CN106336397A (en) * 2015-07-07 2017-01-18 郭明山 Novel compound for treating ophthalmic diseases
CN106478596A (en) * 2015-08-25 2017-03-08 李建成 A kind of noval chemical compound as treatment ophthalmic diseasess

Also Published As

Publication number Publication date
WO2021035360A1 (en) 2021-03-04
AU2020338490B2 (en) 2025-09-18
EP4021912A4 (en) 2023-08-23
IL290798A (en) 2022-04-01
CA3147801A1 (en) 2021-03-04
EP4021912A1 (en) 2022-07-06
AU2020338490A1 (en) 2022-03-17
IL290798B1 (en) 2026-02-01